PCSK9 gene Polymorphism and Assessment of Cardiovascular Risk and Prognosis in Patients With Hyperlipidemia: A Retrospective Cohort Study
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70120 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Aibibanmu Aizezi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Cardiovascular Diseases, Hyperlipidemias. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianshan Talent Training Program, Xinjiang Uygur Autonomous Region, Open Project of the Key Laboratory, Science and Technology Department, Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) polymorphisms exhibit ethnic‐specific associations with cardiovascular risk. However, their prognostic value for major adverse cardiovascular and cerebrovascular events (MACCE) in Asian populations remains undefined. This prospective cohort study enrolled 1969 patients (mean age 54.5 ± 10.7 years, 60.2% male) with hyperlipidemia and followed them for a median of 62 months (IQR 24–89 months). We evaluated the association of three PCSK9 polymorphisms (rs2483205, rs2495477, and rs562556) with metabolic parameters and MACCE. A genotype‐integrated nomogram was developed using Least Absolute Shrinkage and Selection Operator (LASSO) – selected predictors and validated in an independent cohort. The rs2483205 TT, rs2495477 GG, and rs562556 GG genotypes were significantly associated with atherogenic dyslipidemia (elevated triglycerides (TG), low‐density lipoprotein cholesterol (LDL‐C), and lipoprotein(a) [Lp(a)], all p < 0.001) and predicted MACCE risk independently of conventional factors (HR = 2.94, 95% CI: 1.80–4.80 for rs2483205 TT). The nomogram demonstrated excellent discrimination (3 and 4 year area under the curve (AUC) = 0.989, concordance index (C‐index) = 0.868) and calibration (slope = 1.02, 95% CI: 0.98–1.06), with decision curve analysis confirming clinical utility across risk thresholds (20%–75%). Net Reclassification Improvement (NRI) increase of 0.059 and an Integrated Discrimination Improvement (IDI) increase of 0.022. PCSK9 genotyping provides independent prognostic value for MACCE risk stratification in hyperlipidemia, with genotype‐specific effects on cardiovascular outcomes. The developed nomogram offers a precision medicine tool for individualized risk prediction and therapeutic decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
- Xinjiang Key Laboratory of Cardiovascular Disease Research, Urumqi, P.R. China.
ORCID-Profile: Dilare Adi
Förderung
- Tianshan Talent Training Program, Xinjiang Uygur Autonomous Region
- Open Project of the Key Laboratory, Science and Technology Department, Xinjiang Uygur Autonomous Region
Zitieren
APA
Aizezi, A., Meng, F., Li, X., Li, Y., Abuzhalihan, J., Liu, F., Gai, M., Adi, D., & Ma, Y. T. (2025). PCSK9 gene Polymorphism and Assessment of Cardiovascular Risk and Prognosis in Patients With Hyperlipidemia: A Retrospective Cohort Study. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70120
Vancouver
Aizezi A, Meng F, Li X, Li Y, Abuzhalihan J, Liu F, et al. PCSK9 gene Polymorphism and Assessment of Cardiovascular Risk and Prognosis in Patients With Hyperlipidemia: A Retrospective Cohort Study. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70120
BibTeX
@article{Aizezi2025,
author = {Aizezi, Aibibanmu and Meng, Fanhua and Li, Xiaolei and Li, Yanpeng and Abuzhalihan, Jialin and Liu, Fen and Gai, Mintao and Adi, Dilare and Ma, Yi-Tong},
title = {PCSK9 gene Polymorphism and Assessment of Cardiovascular Risk and Prognosis in Patients With Hyperlipidemia: A Retrospective Cohort Study},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70120}
}
EUVIMED